pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 28·1 min read
save

Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spending

Novartis CEO Vas Narasimhan said the Swiss company is “very disappointed” by Germany’s plan to shave off more than €60 billion in healthcare costs that would affect pharma sales. Germany wants to slash its healthcare ...

Apr 28, 2026·read at Endpoints ↗

Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP Images) April 28, 2026 06:35 AM EDTUpdated 01:44 PM Pharma No­var­tis CEO dis­heart­ened by Ger­many’s planned €60B cuts to health­care spend­ing Ayisha Sharma News Reporter No­var­tis CEO Vas Narasimhan said the Swiss com­pa­ny is “very dis­ap­point­ed” by Ger­many’s plan to shave off more than €60 bil­lion in health­care costs that … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
93 words · retrieved Apr 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVARTIS3
topics
Cardiology

related stories

  • 1h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Aug 207 biopharma M&A deals where layoffs followedBioSpace
  • Aug 17EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD raceBioSpace
  • Aug 14STAT+: PBMs agree to display TrumpRx drug pricesSTAT
  • Aug 12STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts saySTAT